Jushi Holdings (JUSHF) Liabilities and Shareholders Equity (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Liabilities and Shareholders Equity of $429.8 million for Q2 2026, down 0.59% year-over-year from $432.4 million in Q2 2025, and down 1.23% quarter-over-quarter from $435.1 million in Q1 2026.
Jushi Holdings (JUSHF) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $429.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity fell 0.59% year-over-year to $429.8 million; the TTM figure through Jun 2026 stood at $1.7 billion (down 1.7% YoY), while the FY2025 annual figure was $422.3 million, down 4.08% from the prior year.
- Liabilities and Shareholders Equity fell to $429.8 million in Q2 2026 per JUSHF's latest filing, from $435.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $710.8 million in Q2 2022 and bottomed at $422.3 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $495.5 million across 5 years, with a median of $456.5 million in 2024.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity retreated 29.44% — and 2026, when it advanced 0.35%.
- Jushi Holdings' Liabilities and Shareholders Equity stood at $529.3 million in 2022, then slipped by 12.46% to $463.4 million in 2023, then declined by 4.98% to $440.3 million in 2024, then fell by 4.08% to $422.3 million in 2025, then grew by 1.77% to $429.8 million in 2026.
- Business Quant data shows JUSHF's Liabilities and Shareholders Equity at $429.8 million in Q2 2026, $435.1 million in Q1 2026, and $422.3 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 6.18 Bn |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | 429.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 429.80 Mn |
| Mar 31, 2026 | 435.14 Mn |
| Dec 31, 2025 | 422.34 Mn |
| Sep 30, 2025 | 431.70 Mn |
| Jun 30, 2025 | 432.37 Mn |
| Mar 31, 2025 | 433.62 Mn |
| Dec 31, 2024 | 440.32 Mn |
| Sep 30, 2024 | 442.33 Mn |
| Jun 30, 2024 | 455.23 Mn |
| Mar 31, 2024 | 457.85 Mn |
| Dec 31, 2023 | 463.40 Mn |
| Sep 30, 2023 | 488.67 Mn |
| Jun 30, 2023 | 501.49 Mn |
| Mar 31, 2023 | 520.04 Mn |
| Dec 31, 2022 | 529.34 Mn |
| Sep 30, 2022 | 665.41 Mn |
| Jun 30, 2022 | 710.77 Mn |
| Mar 31, 2022 | 659.55 Mn |
| Dec 31, 2021 | 652.05 Mn |